Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Relationship of Nocturnal Sleep Dysfunction and Pain Subtypes in Parkinson's Disease.

Martinez-Martin P, Rizos AM, Wetmore JB, Antonini A, Odin P, Pal S, Sophia R, Carroll C, Martino D, Falup-Pecurariu C, Kessel B, Andrews T, Paviour D, Trenkwalder C, Chaudhuri KR; EUROPAR & MDS Non‐Motor PD Study Group.

Mov Disord Clin Pract. 2018 Nov 8;6(1):57-64. doi: 10.1002/mdc3.12694. eCollection 2019 Jan.

PMID:
30746417
2.

Early withdrawal and non-withdrawal death in the months following hemodialysis initiation: A retrospective cohort analysis.

Wetmore JB, Roetker NS, Gilbertson DT, Liu J.

Hemodial Int. 2019 Feb 11. doi: 10.1111/hdi.12723. [Epub ahead of print]

PMID:
30741471
3.

Excess Deaths Attributable to Influenza-Like Illness in the ESRD Population.

Gilbertson DT, Rothman KJ, Chertow GM, Bradbury BD, Brookhart MA, Liu J, Winkelmayer WC, Stürmer T, Monda KL, Herzog CA, Ashfaq A, Collins AJ, Wetmore JB.

J Am Soc Nephrol. 2019 Feb;30(2):346-353. doi: 10.1681/ASN.2018060581. Epub 2019 Jan 24.

PMID:
30679380
4.

Prevalence of chronic kidney disease in the elderly using the ASPirin in Reducing Events in the Elderly (ASPREE) study cohort.

Polkinghorne KR, Wolfe R, Jachno KM, Wetmore JB, McNeil JJ, Nelson MR, Reid CM, Murray AM; ASPREE Investigator Group.

Nephrology (Carlton). 2019 Jan 20. doi: 10.1111/nep.13565. [Epub ahead of print]

PMID:
30663195
5.

Relation of Race, Apparent Disability, and Stroke Risk With Warfarin Prescribing for Atrial Fibrillation in Patients Receiving Maintenance Hemodialysis.

Wetmore JB, Peng Y, Gilbertson DT, Liu J.

Am J Cardiol. 2019 Feb 15;123(4):598-604. doi: 10.1016/j.amjcard.2018.11.020. Epub 2018 Nov 24.

PMID:
30527770
6.

Predialysis anemia management and outcomes following dialysis initiation: A retrospective cohort analysis.

Wetmore JB, Li S, Yan H, Xu H, Peng Y, Sinsakul MV, Liu J, Gilbertson DT.

PLoS One. 2018 Sep 26;13(9):e0203767. doi: 10.1371/journal.pone.0203767. eCollection 2018.

7.

Treatment of secondary hyperparathyroidism: How do cinacalcet and etelcalcetide differ?

Eidman KE, Wetmore JB.

Semin Dial. 2018 Sep;31(5):440-444. doi: 10.1111/sdi.12734. Epub 2018 Jul 15.

PMID:
30009474
8.

Association of Slow Graft Function with Long-Term Outcomes in Kidney Transplant Recipients.

Wang CJ, Tuffaha A, Phadnis MA, Mahnken JD, Wetmore JB.

Ann Transplant. 2018 Apr 3;23:224-231.

9.

Managing hyperparathyroidism in hemodialysis: role of etelcalcetide.

Eidman KE, Wetmore JB.

Int J Nephrol Renovasc Dis. 2018 Feb 5;11:69-80. doi: 10.2147/IJNRD.S128252. eCollection 2018. Review.

10.

Readmissions Following a Hospitalization for Cardiovascular Events in Dialysis Patients: A Retrospective Cohort Study.

Wetmore JB, Molony JT, Liu J, Peng Y, Herzog CA, Collins AJ, Gilbertson DT.

J Am Heart Assoc. 2018 Feb 13;7(4). pii: e007231. doi: 10.1161/JAHA.117.007231.

11.

Factors Associated With Withdrawal From Maintenance Dialysis: A Case-Control Analysis.

Wetmore JB, Yan H, Hu Y, Gilbertson DT, Liu J.

Am J Kidney Dis. 2018 Jun;71(6):831-841. doi: 10.1053/j.ajkd.2017.10.025. Epub 2018 Jan 10.

PMID:
29331476
12.

Insights From the 2016 Peer Kidney Care Initiative Report: Still a Ways to Go to Improve Care for Dialysis Patients.

Wetmore JB, Li S, Molony JT, Guo H, Herzog CA, Gilbertson DT, Peng Y, Collins AJ.

Am J Kidney Dis. 2018 Jan;71(1):123-132. doi: 10.1053/j.ajkd.2017.08.023. Epub 2017 Nov 20.

PMID:
29162336
13.

Clinical characteristics and risk factors associated with mortality in calcific uremic arteriolopathy.

Santos PW, He J, Tuffaha A, Wetmore JB.

Int Urol Nephrol. 2017 Dec;49(12):2247-2256. doi: 10.1007/s11255-017-1721-9. Epub 2017 Oct 20.

PMID:
29058165
14.

The role of parathyroidectomy in the management of secondary hyperparathyroidism.

Eidman KE, Wetmore JB.

Curr Opin Nephrol Hypertens. 2017 Nov;26(6):516-522. doi: 10.1097/MNH.0000000000000365. Review.

PMID:
28985191
15.

Variability in hemoglobin levels in hemodialysis patients in the current era: a retrospective cohort study.

Gilbertson DT, Hu Y, Peng Y, Maroni BJ, Wetmore JB.

Clin Nephrol. 2017 Nov;88(11):254-265. doi: 10.5414/CN109031.

16.

A clinical trial design using the concept of proportional time using the generalized gamma ratio distribution.

Phadnis MA, Wetmore JB, Mayo MS.

Stat Med. 2017 Nov 20;36(26):4121-4140. doi: 10.1002/sim.7421. Epub 2017 Aug 16.

PMID:
28815655
17.

Use of the Medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled populations in the US.

Mues KE, Liede A, Liu J, Wetmore JB, Zaha R, Bradbury BD, Collins AJ, Gilbertson DT.

Clin Epidemiol. 2017 May 9;9:267-277. doi: 10.2147/CLEP.S105613. eCollection 2017. Review.

18.

Myopericarditis in a patient with hepatitis C and cryoglobulinemic renal disease.

Ali MA, Kayani WZ, Linzie BM, Punjabi GV, Wetmore JB.

Clin Case Rep. 2017 Mar 21;5(5):616-620. doi: 10.1002/ccr3.788. eCollection 2017 May.

19.

Relative Incidence of Acute Adverse Events with Ferumoxytol Compared to Other Intravenous Iron Compounds: A Matched Cohort Study.

Wetmore JB, Weinhandl ED, Zhou J, Gilbertson DT.

PLoS One. 2017 Jan 30;12(1):e0171098. doi: 10.1371/journal.pone.0171098. eCollection 2017.

20.

Cholecalciferol v. ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial.

Wetmore JB, Kimber C, Mahnken JD, Stubbs JR.

Br J Nutr. 2016 Dec;116(12):2074-2081. doi: 10.1017/S000711451600427X. Epub 2017 Jan 9.

21.

Geographic variation of parathyroidectomy in patients receiving hemodialysis: a retrospective cohort analysis.

Wetmore JB, Liu J, Dluzniewski PJ, Ishani A, Block GA, Collins AJ.

BMC Surg. 2016 Nov 29;16(1):77.

22.

Comparative Effectiveness of Renin-Angiotensin System Antagonists in Maintenance Dialysis Patients.

Shireman TI, Mahnken JD, Phadnis MA, Ellerbeck EF, Wetmore JB.

Kidney Blood Press Res. 2016;41(6):873-885. doi: 10.1159/000452590. Epub 2016 Nov 21.

24.

Serum Potassium Levels and Mortality in Hemodialysis Patients: A Retrospective Cohort Study.

Yusuf AA, Hu Y, Singh B, Menoyo JA, Wetmore JB.

Am J Nephrol. 2016;44(3):179-86. doi: 10.1159/000448341. Epub 2016 Sep 3.

25.

The Healthy People 2020 Objectives for Kidney Disease: How Far Have We Come, and Where Do We Need to Go?

Wetmore JB, Liu J, Li S, Hu Y, Peng Y, Gilbertson DT, Collins AJ.

Clin J Am Soc Nephrol. 2017 Jan 6;12(1):200-209. doi: 10.2215/CJN.04210416. Epub 2016 Aug 30.

26.

Old versus new: Progress in reaching the goals of the new kidney allocation system.

Wang CJ, Wetmore JB, Israni AK.

Hum Immunol. 2017 Jan;78(1):9-15. doi: 10.1016/j.humimm.2016.08.007. Epub 2016 Aug 12. Review.

PMID:
27527922
27.

The rise of FGF23: should insights from population-based studies inform future clinical trials?

Wetmore JB.

Kidney Int. 2016 Sep;90(3):477-9. doi: 10.1016/j.kint.2016.06.005.

PMID:
27521109
28.

The incidence, prevalence, and outcomes of glomerulonephritis derived from a large retrospective analysis.

Wetmore JB, Guo H, Liu J, Collins AJ, Gilbertson DT.

Kidney Int. 2016 Oct;90(4):853-60. doi: 10.1016/j.kint.2016.04.026. Epub 2016 Jul 15.

PMID:
27425855
29.

Geovariation in Fracture Risk among Patients Receiving Hemodialysis.

Wetmore JB, Liu J, Wirtz HS, Gilbertson DT, Cooper K, Nieman KM, Collins AJ, Bradbury BD.

Clin J Am Soc Nephrol. 2016 Aug 8;11(8):1413-21. doi: 10.2215/CJN.11651115. Epub 2016 Jun 7.

30.

Parathyroidectomy: Complex Decisions about a Complex Procedure.

Wetmore JB.

Clin J Am Soc Nephrol. 2016 Jul 7;11(7):1133-5. doi: 10.2215/CJN.04950516. Epub 2016 Jun 6. No abstract available.

31.

Effects of the prospective payment system on anemia management in maintenance dialysis patients: implications for cost and site of care.

Wetmore JB, Tzivelekis S, Collins AJ, Solid CA.

BMC Nephrol. 2016 May 26;17(1):53. doi: 10.1186/s12882-016-0267-x.

32.

Improving Outcomes in Patients Receiving Dialysis: The Peer Kidney Care Initiative.

Wetmore JB, Gilbertson DT, Liu J, Collins AJ.

Clin J Am Soc Nephrol. 2016 Jul 7;11(7):1297-304. doi: 10.2215/CJN.12981215. Epub 2016 Mar 22.

33.

Shaping Public Health Initiatives in Kidney Diseases: The Peer Kidney Care Initiative.

Wetmore JB, Gilbertson DT, Collins AJ.

Blood Purif. 2016;41(1-3):151-8. doi: 10.1159/000441316. Epub 2016 Jan 15. Review.

34.

Patient characteristics, disease burden, and medication use in stage 4 - 5 chronic kidney disease patients.

Wetmore JB, Peng Y, Jackson S, Matlon TJ, Collins AJ, Gilbertson DT.

Clin Nephrol. 2016 Feb;85(2):101-11. doi: 10.5414/CN108626.

PMID:
26636331
35.

Controlling confounding of treatment effects in administrative data in the presence of time-varying baseline confounders.

Gilbertson DT, Bradbury BD, Wetmore JB, Weinhandl ED, Monda KL, Liu J, Brookhart MA, Gustafson SK, Roberts T, Collins AJ, Rothman KJ.

Pharmacoepidemiol Drug Saf. 2016 Mar;25(3):269-77. doi: 10.1002/pds.3922. Epub 2015 Nov 26.

PMID:
26608680
36.

Infections Requiring Hospitalization in Patients on Hemodialysis.

Gilbertson DT, Wetmore JB.

Clin J Am Soc Nephrol. 2015 Dec 7;10(12):2101-3. doi: 10.2215/CJN.10891015. Epub 2015 Nov 13. No abstract available.

37.

An ensemble survival model for estimating relative residual longevity following stroke: Application to mortality data in the chronic dialysis population.

Phadnis MA, Wetmore JB, Shireman TI, Ellerbeck EF, Mahnken JD.

Stat Methods Med Res. 2017 Dec;26(6):2667-2680. doi: 10.1177/0962280215605107. Epub 2015 Sep 24.

38.

The association of chronic kidney disease with the use of renin-angiotensin system inhibitors after acute myocardial infarction.

Wetmore JB, Tang F, Sharma A, Jones PG, Spertus JA.

Am Heart J. 2015 Oct;170(4):735-43. doi: 10.1016/j.ahj.2015.07.019. Epub 2015 Jul 26.

39.

Relationship between calcium channel blocker class and mortality in dialysis.

Wetmore JB, Mahnken JD, Phadnis MA, Ellerbeck EF, Shireman TI.

Pharmacoepidemiol Drug Saf. 2015 Dec;24(12):1249-58. doi: 10.1002/pds.3869. Epub 2015 Sep 15.

40.

Changes in secondary hyperparathyroidism-related biochemical parameters and medication use following parathyroidectomy.

Wetmore JB, Liu J, Do TP, Lowe KA, Ishani A, Bradbury BD, Block GA, Collins AJ.

Nephrol Dial Transplant. 2016 Jan;31(1):103-11. doi: 10.1093/ndt/gfv291. Epub 2015 Aug 19.

PMID:
26292694
41.

Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden.

Stubbs JR, House JA, Ocque AJ, Zhang S, Johnson C, Kimber C, Schmidt K, Gupta A, Wetmore JB, Nolin TD, Spertus JA, Yu AS.

J Am Soc Nephrol. 2016 Jan;27(1):305-13. doi: 10.1681/ASN.2014111063. Epub 2015 Jul 30.

42.

Meeting the World's Need for Maintenance Dialysis.

Wetmore JB, Collins AJ.

J Am Soc Nephrol. 2015 Nov;26(11):2601-3. doi: 10.1681/ASN.2015060660. Epub 2015 Jul 24. No abstract available.

43.

Trends in anemia management practices in patients receiving hemodialysis and peritoneal dialysis: a retrospective cohort analysis.

Wetmore JB, Peng Y, Monda KL, Kats AM, Kim DH, Bradbury BD, Collins AJ, Gilbertson DT.

Am J Nephrol. 2015;41(4-5):354-61. doi: 10.1159/000431335. Epub 2015 Jun 17.

PMID:
26107376
44.

Ergocalciferol versus Cholecalciferol for Nutritional Vitamin D Replacement in CKD.

Mangoo-Karim R, Da Silva Abreu J, Yanev GP, Perez NN, Stubbs JR, Wetmore JB.

Nephron. 2015;130(2):99-104. doi: 10.1159/000430813. Epub 2015 Jun 2.

PMID:
26044704
45.

A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM).

Wetmore JB, Gurevich K, Sprague S, Da Roza G, Buerkert J, Reiner M, Goodman W, Cooper K.

Clin J Am Soc Nephrol. 2015 Jun 5;10(6):1031-40. doi: 10.2215/CJN.07050714. Epub 2015 Apr 22.

46.

Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.

Sprague SM, Wetmore JB, Gurevich K, Da Roza G, Buerkert J, Reiner M, Goodman W, Cooper K.

Clin J Am Soc Nephrol. 2015 Jun 5;10(6):1021-30. doi: 10.2215/CJN.03270314. Epub 2015 Apr 14.

47.

The Donor Kidney Biopsy and Its Implications in Predicting Graft Outcomes: A Systematic Review.

Wang CJ, Wetmore JB, Crary GS, Kasiske BL.

Am J Transplant. 2015 Jul;15(7):1903-14. doi: 10.1111/ajt.13213. Epub 2015 Mar 13. Review.

48.

Association between higher rates of cardioprotective drug use and survival in patients on dialysis.

Tang Y, Brooks JM, Wetmore JB, Shireman TI.

Res Social Adm Pharm. 2015 Nov-Dec;11(6):824-43. doi: 10.1016/j.sapharm.2014.12.007. Epub 2014 Dec 31.

49.

Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis.

Ishani A, Liu J, Wetmore JB, Lowe KA, Do T, Bradbury BD, Block GA, Collins AJ.

Clin J Am Soc Nephrol. 2015 Jan 7;10(1):90-7. doi: 10.2215/CJN.03520414. Epub 2014 Dec 16.

50.

Estimation of Drug Effectiveness by Modeling Three Time-dependent Covariates: An Application to Data on Cardioprotective Medications in the Chronic Dialysis Population.

Phadnis MA, Shireman TI, Wetmore JB, Rigler SK, Zhou X, Spertus JA, Ellerbeck EF, Mahnken JD.

Stat Biopharm Res. 2014;6(3):229-240.

Supplemental Content

Loading ...
Support Center